At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 200 enrolled
Drug / intervention
CTX-4430 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
In Brief
A Phase 2 clinical trial evaluating CTX-4430 and Placebo for Cystic Fibrosis. Completed, enrolled 200 participants across 75 sites in 7 countries.
Detailed Summary
This study is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of CTX-4430 administered once-daily for 48 weeks for treatment of CF.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesBelgium, Canada, France, Germany, Italy, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartOct 2015
Primary CompletionApr 2018
Study CompletionMay 2018
TodayJul 2026
First PostedMay 14, 2015
Enrollment StartOct 30, 2015
Primary CompletionApr 20, 2018
Study CompletionMay 16, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 11.1 years ago
Interventions
CTX-4430drug
Placebodrug